Hospira Recalls Bupivacaine HCl Injection
The company voluntarily recalls Preservative-Free Bupivacaine HCl Injection, USP due to potential iron oxide particulates.
Hospira announced on April 23, 2015 it was voluntarily recalling one lot of Preservative-Free Bupivacaine hydrochloride (HCl) Injection, USP, 0.5% (5 mg/mL), 30 mL Single-dose (NDC: 0409-1162-02, Lot 38-515-DK, Expiry 1FEB2016). The recall comes after confirmed complaints from a customer of orange and black, visible particles found in a single-dose glass teartop vial. The recalled lot was distributed from July to September 2014.
Hospira has identified the particles as iron oxide and is investigating the root cause of the particulates. The company says it working with their glass supplier as part of the investigation.
Source: FDA.gov
Market Demands and Emerging Technologies Shape Outsourcing Models
June 5th 2025Trends in certain forms of drug delivery, as well as the emergence of artificial intelligence, are playing roles in evolving the nature of partnerships, but there are new types of partnerships gaining steam as well.
Guidance on Quality Culture Standards
June 3rd 2025Matt Cushing, VP of Quality and Science, Nelson Labs, and Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs Company, discuss PDA/ANSI Standard 06-2025: Assessment of Quality Culture Guidance Documents, Models, and Tools, which was published in February 2025.
